UniProt O75716 · PDB · AlphaFold · Substrate: MBP · Clone: full lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Abemaciclib | 94.6% | 5.4% | 91.48 | 0.563 |
| 2 | Gilteritinib | 90.2% | 9.8% | 88.97 | 0.506 |
| 3 | Defactinib | 85.2% | 14.8% | 92.68 | 0.450 |
| 4 | Palbociclib | 78.1% | 21.9% | 98.75 | 0.673 |
| 5 | Pacritinib | 75.5% | 24.5% | 88.64 | 0.452 |
| 6 | Midostaurin | 61.3% | 38.7% | 78.64 | 0.500 |
| 7 | Fostamatinib | 59.5% | 40.5% | 96.74 | 0.613 |
| 8 | Fedratinib | 50.6% | 49.4% | 96.21 | 0.576 |
| 9 | Sunitinib | 47.4% | 52.6% | 91.73 | 0.524 |
| 10 | Pazopanib | 41.6% | 58.4% | 97.49 | 0.672 |
| 11 | Ponatinib | 33.1% | 66.9% | 78.23 | 0.534 |
| 12 | Nintedanib | 31.8% | 68.2% | 90.23 | 0.608 |
| 13 | Pralsetinib | 27.3% | 72.7% | 93.43 | 0.643 |
| 14 | Avapritinib | 27.2% | 72.8% | 97.73 | 0.644 |
| 15 | Alectinib | 25.6% | 74.4% | 95.49 | 0.651 |
| 16 | Selpercatinib | 18.0% | 82.0% | 96.72 | 0.635 |
| 17 | Brigatinib | 15.7% | 84.3% | 82.96 | 0.513 |
| 18 | Rabusertib | 15.6% | 84.4% | 98.74 | 0.687 |
| 19 | Axitinib | 15.5% | 84.5% | 93.23 | 0.688 |
| 20 | Abrocitinib | 14.7% | 85.3% | 99.50 | 0.581 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 5.03
- Epithelial log2(TPM+1): 4.86
- Fold change: 0.17
- Status: No significant change
High-confidence drugs
- Abemaciclib — inh 94.6% · KISS 31.59
- Palbociclib — inh 78.1% · KISS 28.41
- Gilteritinib — inh 90.2% · KISS 22.56
Selectivity landscape vs inhibition on STK16
Each point is one of the 92 approved drugs; color = inhibition % on STK16.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…